Gilead Sciences, Inc. (NASDAQ:GILD) Coverage Initiated at Oppenheimer Holdings, Inc.

Stock analysts at Oppenheimer Holdings, Inc. initiated coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a note issued to investors on Thursday, October 5th, Marketbeat reports. The firm set a “market perform” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on GILD. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target for the company. in a research note on Wednesday, June 21st. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on Gilead Sciences in a research note on Friday, June 23rd. They issued a “buy” rating and a $79.00 price target for the company. Twelve research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $85.80.

Shares of Gilead Sciences (NASDAQ GILD) traded up 0.09% on Thursday, hitting $80.02. 2,527,402 shares of the stock were exchanged. The stock has a market cap of $104.50 billion, a price-to-earnings ratio of 8.69 and a beta of 1.14. The stock’s 50-day moving average is $82.48 and its 200-day moving average is $72.25. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the prior year, the company posted $3.08 EPS. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. Analysts forecast that Gilead Sciences will post $8.76 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://baseballnewssource.com/markets/oppenheimer-holdings-inc-begins-coverage-on-gilead-sciences-inc-gild/1699359.html.

In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction on Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares in the company, valued at approximately $10,174,112. The disclosure for this sale can be found here. In the last quarter, insiders have sold 486,819 shares of company stock worth $39,298,919. 1.30% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the business. Seizert Capital Partners LLC raised its position in shares of Gilead Sciences by 4.6% in the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after buying an additional 27,547 shares during the period. Linscomb & Williams Inc. raised its position in shares of Gilead Sciences by 3.0% in the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares during the period. Investment Centers of America Inc. raised its position in shares of Gilead Sciences by 7.2% in the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,958 shares during the period. HealthInvest Partners AB raised its position in shares of Gilead Sciences by 3.5% in the 1st quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock worth $7,947,000 after buying an additional 4,000 shares during the period. Finally, Capital Asset Advisory Services LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth $875,000. 73.97% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.